Natera Inc.
Natera, Inc. Approves Amendment to Equity Incentive Plan at Annual Meeting
Summary
On June 11, 2026, Natera, Inc. held its Annual Meeting of Stockholders where the Company's stockholders approved an amendment to the Amended and Restated 2015 Equity Incentive Plan, increasing the shares reserved for issuance by 3.2 million shares. The amendment was approved by a significant majority of the votes cast. Additionally, the meeting saw the election of directors and ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement